19 September 2011 – Quotient Bioresearch has today announced its adoption of Bruker’s MALDI Biotyper for bacterial identification, following a successful year-long trial.
The announcement, made at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 17-20, Chicago, US) where Quotient will be presenting a series of posters, places the company in a unique position as the first GLP laboratory to adopt the technology for routine bacterial identification as part of its portfolio of services for antimicrobial development.
Dr Ian Morrissey, Director of Microbiology at Quotient, commented: “Quotient’s expert Bioanalytical Sciences team is a fusion of microbiology, immunochemistry and mass-spectrometry specialists, which means we are perfectly placed to embrace this technology.”
Delivering rapid and precise identification, Bruker’s MALDI Biotyper technology enables Quotient to identify many thousands of organisms a year for antibiotic resistance surveillance, in a much more efficient and accurate manner than traditional identification methods.
Craig Parker, Global Market Manager for Microbiology at Bruker Daltonics, said: “It’s great to see Quotient embracing our MALDI Biotyper technology and encompassing it within its own technical work.”
Ian added: “The trial period of Bruker’s MALDI Biotyper has proved very successful and we are confident that this technology represents the future of bacterial identification, and Quotient is proud to be at the forefront of this exciting field.”
Quotient will be presenting two posters on MALDI-TOF technology at ICAAC.
‘D-1285 - Large Scale Performance Evaluation of MALDI-TOF MS in a Central Reference Laboratory Setting’ is the largest industry study into MALDI-TOF and ‘D-1284 - Rapid Identification of Veterinary Enterococci by MALDI-TOF MS’ analyses how MALDI-TOF technology can aid better identification of bacteria over traditional industry methods.
Quotient Bioresearch is exhibiting at booth number 335 during the conference. Bruker Daltonics is exhibiting at booth number 813.
For further information, or to arrange a meeting, visit the website at www.quotientbioresearch.com/bioanalytical-sciences or email [email protected]
About Quotient Bioresearch Ltd.
Quotient Bioresearch is a leading provider of early stage and specialist drug development services to life science clients worldwide. We provide tailored solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled medical, chemical and biological expertise. Our consultative, science-driven approach ensures the highest quality service to support and accelerate new product development. Our extensive range of capabilities spans Chemistry and Metabolism, Bioanalytical Sciences, and Clinical. These can be provided independently or integrated into bespoke work programmes.
An early acquisition for Quotient was London-based GR Micro Ltd., bringing to the group more than 25 years’ experience in antimicrobial discovery and development, and now availed of state-of-the-art, purpose-built laboratories within our Cambridgeshire site. Internationally recognised as leaders in providing true expertise in antimicrobial development, we are dedicated to supporting projects of all sizes, from early discovery through to late-phase clinical trials and global resistance surveillance studies.